Pharmaceutical company Pfizer said it’s moving forward with trials of its COVID-19 vaccine for children between the ages of five and 11, and expects to make the vaccine available in the fall.
If studies show a good immune response and safety, it will then launch the vaccine for children aged six months to five.
Pfizer developed its vaccine in partnership with German biotechnology company BioNTech.
The drugmaker is testing its vaccine at lower doses in three different age groups: five to 11 years, two to five years, and six months to two years, to examine vaccine efficacy, safety, and immunity.
The vaccine’s effectiveness will be worked out by comparing the participants’ immune responses to the “16–25-year-old population from the pivotal Phase 3 trial, as vaccine efficacy has been demonstrated in this age group,” Pfizer said.
The children will be given two injections of either the vaccine or a placebo spaced three weeks apart. Those aged five to 11 will receive 10 micrograms each, while the younger age group will get three micrograms each.
Around 4,500 children will be enrolled at clinical sites in the United States, Spain, Finland, and Poland.
Pfizer also said that infants younger than six months may be considered for vaccination “once an acceptable safety profile has been established.”
While the trial is expected to last for two years, Pfizer said that all the participants will be unblinded, or told whether they received the vaccine or a placebo, at a six-month follow-up visit. Those who originally got the placebo will be offered the vaccine.
The FDA expanded the use of Pfizer’s vaccine to 12- to 15-year-olds on May 10, with the Centers for Disease Control and Prevention (CDC) issuing a recommendation two days later.
Doctors say parents shouldn’t be too alarmed about the rare condition.
The rush by health officials and the government to vaccinate healthy children and adolescents without adequate safety data is concerning to some experts and parents, as severe COVID-19 illness is rare among this age group, and deaths from the disease even rarer. Furthermore, young children aren’t super-spreaders of the virus.
“There’s a train leaving the station, and everyone is jumping on it and it makes me a little bit nervous. It’s too fast.”
Parent Janci Lindsay, a toxicologist and molecular biologist, said that children shouldn’t be inoculated with a COVID-19 vaccine that isn’t FDA-approved and lacks long-term safety data.
“Multiple studies show that infants and children are not at significant risk for morbidity or mortality from COVID-19,” Lindsay said in a public comment to the vaccine advisory committee on May 12, adding that the infection fatality ratio (IFR) for the different age groups were minuscule: “0.003 [percent] for the 0–4 age group, 0.001 [percent] for the 5–9 age group, 0.001 [percent] for the 10–14 age group, and 0.003 [percent] for the 15–19 age group.”
The IFR estimates the number of deaths from COVID-19 among all infected individuals.
Barbara Loe Fisher, co-founder and president of the National Vaccine Information Center, said parents aren’t able to make an informed decision without all of the “adequate scientific evidence” on the safety and efficacy of the vaccine.
“The FDA has stated that ‘there is no information on the co-administration on the Pfizer-BioNTech COVID-19 vaccine with other vaccines,’ but the CDC has chosen to assume safety,” Fisher told The Epoch Times via email in May. “They have given the green light for medical workers to administer Pfizer’s still experimental vaccine to adolescent children in combination with influenza, meningococcal, HPV, Tdap, and other CDC recommended vaccines on the same day.”
“Why are parents being put in the position of playing vaccine roulette? Why are federal lawmakers allowing the FDA and CDC to get away with simply assuming COVID vaccine safety rather than proving it?”